.png){kind=icon}
.png){kind=icon}
Return
Target proteomics-based analysis of the deep association between USP30 and prognosis of glioblastoma multiforme
.png){kind=icon}
OA
AI
C
Y
X
W
DOI：10.1097/JS9.0000000000003861.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Glioblastoma Multiforme(GBM) is the most common primary malignant tumor of the central nervous system and the most prevalent primary malignant brain tumor in adults, accounting for over 50% of adult malignant primary brain tumors. Adult patients with GBM have a median age at onset ranging from 45.5 to 56 years, with no significant gender difference, and the 5-year survival rate is only 5%–10%. Despite the advancements in surgery and chemoradiotherapy, prognosis remains poor. There is an urgent need to identify novel therapeutic targets and prognostic biomarkers for GBM. Ubiquitin-specific protease 30 (USP30), a member of the deubiquitinating enzyme family, has been implicated in tumor progression. This study investigates the potential mechanisms of USP30 in GBM using proteomic analysis and functional validation. It further explores USP30’s potential as a prognostic marker and therapeutic target in GBM, focusing on its downregulation and possible role in tumor suppression.
Keywords:
Deubiquitinating Enzyme
GBM
Proteomics
USP30
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
10.1
Papers:
7.9K
Citations:
2.2W
Organization
No organization information available
Cited Papers